Vitamin D5
| |
| Nazivi | |
|---|---|
| IUPAC naziv
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,4S)-4-etil-1,5-dimetilheksil]-7a-metil-2,3,3a,5,6,7-heksahidro-1H-inden-4-iliden]etiliden]-4-metilen-1-cikloheksanol
| |
| Identifikacija | |
3D model (Jmol)
|
|
| ChemSpider | |
| |
| Svojstva | |
| C29H48O | |
| Molarna masa | 412,69 |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
 verifikuj (šta je   ?)
| |
| Reference infokutije | |
Vitamin D5 je oblik vitamina D.
Analogna jedinjenja su predložena za upotrebu kao antitumorski agensi.[3][4][5]
Reference
[уреди | уреди извор]- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ Mehta RG; Moriarty RM; Mehta RR; et al. (1997). „Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5”. J. Natl. Cancer Inst. 89 (3): 212—8. PMID 9017001. doi:10.1093/jnci/89.3.212.
- ^ Murillo G, Mehta RG (2005). „Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5”. J. Steroid Biochem. Mol. Biol. 97 (1-2): 129—36. PMID 16051482. doi:10.1016/j.jsbmb.2005.06.008.
- ^ Mehta RG (2004). „Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5”. Eur. J. Cancer. 40 (15): 2331—7. PMID 15454260. doi:10.1016/j.ejca.2004.05.025.
